AtaiBeckley is a clinical-stage biopharmaceutical company focused on developing rapid-acting mental health therapies, including psychedelic-based neuroplastogens. The company was formed through the successful 2025 strategic combination of atai Life Sciences and Beckley Psytech. It trades on Nasdaq under ATAI.
FDA final guidance sets standards for psychedelic clinical trials. Federal agencies and states are advancing psilocybin and ibogaine research, and Eli Lilly is acquiring AtaiBeckley for $2.8 billion.
Multiple biopharma companies appointed new chief financial officers in early 2026, including clinical-stage and publicly traded firms. The appointments bring executives with backgrounds in investment banking, life sciences finance, and commercial operations.
Compass Pathways reported positive late-stage COMP360 psilocybin data in treatment-resistant depression and plans FDA talks ahead of a filing between October and December. The update lifted shares across several psychedelics developers.
Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.
